Sildenafil in ophthalmology: An update.

Supriya Arora, Thamolwan Surakiatchanukul, Tarun Arora, Carlo Cagini, Marco Lupidi, Jay Chhablani

Survey of ophthalmology 2022 Mar-Apr

filter terms:

Sildenafil citrate, a selective oral phosphodiesterase 5 inhibitor, is a widely used drug for erectile dysfunction that acts by elevating cGMP levels and causing smooth muscle relaxation. It also has 10% activity against PDE6, a key enzyme in phototransduction cascade in the retina. Recent ocular imaging developments have further revealed the influence of sildenafil on ocular hemodynamics, particularly choroidal perfusion. Choroidal thickness is increased, and choroidal perfusion is also enhanced by autoregulatory mechanisms that are further dependent on age and microvascular abnormalities. Studies demonstrating high intraocular pressure via a "parallel pathway" from increased choroidal volume and blood flow to the ciliary body have challenged previous concepts. Another new observation is the effect of sildenafil on bipolar cells and cyclic-nucleotide gated channels. We discuss potential deleterious effects (central serous chorioretinopathy, glaucoma, ischemic optic neuropathy, and risks to recessive carriers of retinitis pigmentosa), potential beneficial effects (ameliorate choroidal ischemia, prevent thickening of Bruch membrane, and promote recovery of the ellipsoid zone) in macular degeneration, as well as potential drug interactions of sildenafil. Copyright © 2021. Published by Elsevier Inc.

Citation

Supriya Arora, Thamolwan Surakiatchanukul, Tarun Arora, Carlo Cagini, Marco Lupidi, Jay Chhablani. Sildenafil in ophthalmology: An update. Survey of ophthalmology. 2022 Mar-Apr;67(2):463-487